Key insights from lung cancer research at ASCO 2025
Dr Triparna Sen speaks to ecancer about her recent study regarding ferroptosis regulator as a novel therapeutic target for STK11/KEAP1 co-mutant lung adenocarcinoma.
In this interview, she talks about what her study was about and what were the initial findings that led to the further development of the study.
She talks about the concept of ferroptosis and explains in detail what it entails. She refers to her paper which explores this concept.
In the end, she explains STK11 and KEAP1 mutations which can be observed in some types of lung cancer and the therapeutic options available for them.
For information regarding the related paper see here.
Key insights from lung cancer research at ASCO 2025
ELCC 2025: Latest in EGFR positive NSCLC
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus